Healthcare

Share

Facebook Twitter Linkedin

Race Oncology Ltd (ASX:RAC)

1.245 AUD

+0.020 1.633%

Last Updated at: 2025-05-09T06:10:00Z

Risk Disclaimer RAC chart by TradingView

Back to ASX:RAC

Risk Disclaimer RAC chart by TradingView

Sponsored Reports

Loading...

Previous Close (in AUD)	1.225
Change	+0.020 1.633%
52 W H/L (in AUD)	2.090/0.920
EBITDA (in AUD)	-7.944M
PE Ratio	--
Volume	134171
Diluted Eps TTM	-0.05

Total Assets (in AUD)	20.229M
Total Liabilities (in AUD)	1.916M
Revenue TTM (in AUD)	5.255M
Cash (in AUD)	1.389M
Market Cap (in AUD)	210.204 M
Revenue Per Share TTM	0.031
Gross Profit TTM (in AUD)	4.105M

Summary

---

Income Statement

Balance Sheet

Change in Cash

Operating Cash

Race Oncology Ltd

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.

Gateway, 1 Macquarie Place, Sydney, NSW, Australia, 2000

61 2 8051 3043

https://www.raceoncology.com

Key Executives

Sr. No.	Name	Title	Year Born
1.	Mr. Phillip R. Lynch	CEO, MD & Director	NA
2.	Dr. Daniel Tillett	Chief Scientific Officer & Exec. Director	NA
3.	Ms. Christina Manfre	Chief Financial Officer	NA
4.	Dr. Ajay Duggal Dip Pharm Med, MB ChB, MRCP	Interim Chief Medical Officer	NA
5.	Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD	Company Sec.	1963
6.	Dr. Daniel Tillett	Chief Executive Officer	NA
7.	Dr. Peter M. Smith Ph.D.	Executive Director	1963
8.	Prof. Tim Hammond	Interim Chief Scientific Officer	NA
9.	Dr. Michelle Rashford	Chief Medical Officer	NA
10.	Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.	Company Secretary	1963

Peers

Sector: Healthcare

Industry: Biotechnology

Company	Change (AUD)	Price (AUD)	Trailing PE(x)	Forward PE(x)	Price Sales TTM(x)	Price to Book Value(x)	Enterprise Value to Revenue(x)	Enterprise Value to EBITDA(x)
CSL CSL Ltd	-0.610 0.254%	239.2	29.920	35.336	8.039	4.318	6.166	19.136
TLX Telix Pharmaceuticals Ltd	+0.180 0.676%	26.88	209.430	67.114	12.462	17.178	12.298	104.073
MSB Mesoblast Ltd	-0.040 2.292%	1.75	0.000	454.546	390.849	3.185	67.899	-9.862
NEU Neuren Pharmaceuticals Ltd	+0.490 3.828%	13.19	11.330	72.464	7.290	4.326	6.341	7.701

• Income Statement
• Balance Sheet
• Cash Flow

Income Statement

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020	30-06-2019
Income Before Tax	-9.923M	-11.202M	-6.34M	-3.846M	-3.659M
Minority Interest	-	-	-	-	-
Net Income	-9.923M	-11.202M	-6.34M	-3.846M	-3.414M
Selling General Administrative	1.445M	3.782M	2.739M	1.577M	1.208M
Gross Profit	1.108M	-0.282M	-0.233M	-0.284M	-0.304M
Reconciled Depreciation	0.281M	0.281M	0.281M	0.281M	0.281M
Ebit	-13.65M	-11.964M	-6.784M	-4.112M	-3.905M
Ebitda	-13.368M	-11.683M	-6.503M	-3.831M	-3.624M
Depreciation And Amortization	0.281M	0.281M	0.281M	0.281M	0.281M
Operating Income	-10.476M	-11.203M	-6.359M	-3.931M	-3.905M
Other Operating Expenses	-9.597M	-9.983M	-5.506M	-3.128M	3.905M
Interest Expense	-	0.054M	0M	0M	0M
Tax Provision	0M	0M	0M	0M	0M
Interest Income	0.592M	0.054M	0.019M	0.009M	0.017M
Net Interest Income	0.592M	0.054M	0.019M	0.009M	0.017M
Income Tax Expense	-0.592M	-0.054M	-0.019M	-0.009M	-0.246M
Total Revenue	3.134M	0.708M	0.387M	0.159M	0.017M
Total Operating Expenses	13.65M	11.964M	6.784M	4.112M	3.905M
Cost Of Revenue	2.026M	0.99M	0.62M	0.443M	0.532M
Total Other Income Expense Net	3.134M	0.708M	0.425M	0.256M	0.246M
Net Income From Continuing Ops	-9.923M	-11.202M	-6.34M	-3.846M	-3.659M
Net Income Applicable To Common Shares	-9.923M	-11.202M	-6.34M	-3.846M	-3.659M

Balance Sheet

(Currency in AUD)

Breakdown	30-06-2024	30-06-2023	30-06-2022	30-06-2021	30-06-2020
Total Assets	20.229M	26.638M	37.525M	14.246M	5.934M
Intangible Assets	-	3.093M	3.374M	3.656M	3.937M
Other Current Assets	0.122M	-	0.547M	1.139M	-0M
Total Liab	1.916M	1.152M	1.417M	0.523M	0.244M
Total Stockholder Equity	18.312M	25.486M	36.107M	13.722M	5.69M
Other Current Liab	0.669M	0.513M	0.584M	0.211M	0.111M
Common Stock	66.948M	61.709M	62.017M	31.495M	19.66M
Capital Stock	-	61.709M	62.017M	31.495M	19.66M
Retained Earnings	-57.418M	-43.599M	-33.675M	-22.466M	-15.771M
Good Will	-	-	-	-	-
Other Assets	-	-	-	-	-
Cash	1.389M	21.52M	33.541M	9.322M	1.731M
Cash And Equivalents	-	-	-	-	-
Total Current Liabilities	1.868M	1.152M	1.417M	0.523M	0.244M
Current Deferred Revenue	-	-	-	-	-
Net Debt	-1.389M	-21.52M	-33.541M	-9.322M	-1.731M
Short Term Debt	-	0M	0M	0M	0M
Short Long Term Debt	-	-	-	-	-
Short Long Term Debt Total	-	-	-	-	-
Other Stockholder Equity	-	-18.11M	-28.341M	-9.029M	-3.889M
Property Plant Equipment	-	-	-	-	-
Total Current Assets	17.417M	23.545M	34.15M	10.59M	1.997M
Long Term Investments	-	-	-	-	-
Short Term Investments	15.8M	-	-	-	-
Net Receivables	0.106M	1.704M	0.062M	0.128M	0.049M
Long Term Debt	-	-	-	-	-
Inventory	-	-	-	-	0.217M
Accounts Payable	1.199M	0.639M	0.834M	0.312M	0.133M
Accumulated Other Comprehensive Income	8.782M	7.376M	7.766M	4.693M	1.801M
Non Currrent Assets Other	-	-3.093M	-3.374M	-3.656M	-3.937M
Non Current Assets Total	2.812M	3.093M	3.374M	3.656M	3.937M
Capital Lease Obligations	-	-	-	-	-
Long Term Debt Total	-	0M	0M	0M	0M

Cash Flow

(Currency in AUD)

Breakdown	30-06-2023	30-06-2022	30-06-2021	30-06-2020	30-06-2019
Investments	-	-	-	-	-
Total Cashflows From Investing Activities	0M	-	-	0M	0M
Total Cash From Financing Activities	-1.283M	30.514M	12.28M	3.21M	-0.034M
Net Income	-9.923M	-11.202M	-6.34M	-3.846M	-3.414M
Change In Cash	-12.02M	24.218M	7.592M	0.742M	-2.721M
Begin Period Cash Flow	33.541M	9.322M	1.731M	0.989M	3.71M
End Period Cash Flow	21.52M	33.541M	9.322M	1.731M	0.989M
Total Cash From Operating Activities	-10.652M	-6.258M	-4.698M	-2.463M	-2.674M
Depreciation	0.281M	0.281M	0.281M	0.281M	0.281M
Other Cashflows From Investing Activities	0M	-	-	0M	0M
Dividends Paid	-	-	-	-	-
Change To Inventory	-	-	-	-	-
Sale Purchase Of Stock	-1.283M	-0.463M	-0.511M	-0.142M	-0.034M
Other Cashflows From Financing Activities	-1.283M	-0M	-0.511M	0.011M	-3.341M
Capital Expenditures	0M	0M	0M	0M	0M
Change In Working Capital	-1.642M	0.066M	-0.079M	-0.048M	-1.918M
Other Non Cash Items	-1.009M	4.663M	1.362M	1.102M	3.378M
Free Cash Flow	-10.652M	-6.258M	-4.698M	-2.463M	-2.674M

No data found

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Advertise your brand on Kalkine Media

By submitting your details and clicking on the Register button below, you agree to Kalkine Media's Terms of Use and agree to receive marketing offers, including to be contacted by e-mail or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine Solutions Private Limited on our behalf or on behalf of Kalkine Pty Ltd.

Submit

Loading...

• Top Gainer
• Top Loser